Search Results - "Blue, Kirsten"

Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer by Fusco, Michael J, Saeed-Vafa, Daryoush, Carballido, Estrella M, Boyle, Theresa A, Malafa, Mokenge, Blue, Kirsten L, Teer, Jamie K, Walko, Christine M, McLeod, Howard L, Hicks, J Kevin, Extermann, Martine, Fleming, Jason B, Knepper, Todd C, Kim, Dae Won

“…It has recently been described that alternative oncogenic drivers may be found in wild-type ( ) pancreatic cancers. This study aimed to determine the incidence…”
Get more information

Sensitivity and Specificity of the NETest: A Validation Study by Al-Toubah, Taymeyah, Cives, Mauro, Valone, Tiffany, Blue, Kirsten, Strosberg, Jonathan

“…Secretory tumor markers traditionally measured in patients with neuroendocrine tumors (NET) are lacking sensitivity and specificity, and consequently they are…”
Get more information

Efficacy of olaparib therapy in metastatic pancreatic ductal adenocarcinoma (PDAC) with homologous recombination deficiency (HRD) by Tan, Elaine, Hicks, James Kevin, Blue, Kirsten, Kim, Richard D., Carballido, Estrella M., Kim, Dae Won

“…Abstract only e16266 Background: Pancreatic cancer is one of the deadliest malignancies, with a 5 year OS of around 3%. Up to 3% of unselected patients (pts)…”
Get full text

Investigate the efficacy of immunotherapy for treatment of pancreatic adenocarcinoma (PDAC) with mismatch repair deficiency (dMMR) by Noor, Arish, Aguirre, Luis E., Blue, Kirsten, Avriett, Trenton, Carballido, Estrella M., Kim, Richard D., Kim, Dae Won

“…Abstract only 415 Background: Immune checkpoint inhibitors (ICI) have been approved in solid tumors with dMMR. However, only limited data are available for…”
Get full text

A phase II study of TAS-102 (FTD/TPI) in combination with ramucirumab (RAM) in advanced, refractory gastric (GC) or gastroesophageal junction (GEJ) adenocarcinomas (GEAs) by Mehta, Rutika, Kim, Richard D., Martinez Jimenez, Maria E, Blue, Kirsten, Avriett, Trenton, Kelbert, Emily, Miller, Kara, Ray, Christopher, Valone, Tiffany, Lee, Woojoo, Kim, Youngchul, Kim, Dae Won

“…Abstract only 302 Background: The RAINBOW trial established the standard of care for treatment of metastatic GEAs with ramucirumab and paclitaxel after failure…”
Get full text

Sensitivity and specificity of the NETest: A validation study by Al-Toubah, Taymeyah E., Cives, Mauro, Valone, Tiffany, Blue, Kirsten, Strosberg, Jonathan R.

“…Abstract only 222 Background: Secretory tumor markers traditionally measured in patients with NET, such as chromogranin A, are lacking in sensitivity and…”
Get full text

PARP Inhibitors in Pancreatic Cancer with Homologous Recombination Repair Gene Mutations: A Single-Institution Experience by Miao, Ruoyu, Blue, Kirsten, Sommerer, Katelyn, Shah, Anand, Bottiglieri, Sal, Del Cueto, Alex, Berry, Darcy K, Ho, Teresa T, Hicks, James Kevin, Kim, Dae Won

“…Limited data are available regarding the anticancer activity of PARP inhibitors (PARPis) in pancreatic cancer with mutations in HRR genes other than and . We…”
Get full text

Optimizing the Management of Carcinoid Syndrome to Reduce the Impact of Diarrhea by Randall, Rory, Bennett, Bonita, Valone, Tiffany, Blue, Kirsten

“…Diarrhea is often a presenting symptom in patients with neuroendocrine tumors (NETs). Frequently diagnosed in advanced stages, carcinoid syndrome diarrhea…”
Get full text